Amit Gupta Joins Intas Pharmaceuticals as Assistant General Manager, Bringing 15+ Years of Regulatory Expertise
Amit Gupta has stepped into the role of Assistant General Manager at Intas Pharmaceuticals, marking a new chapter in his distinguished career in regulatory affairs and quality management. With over 15 years of experience across the pharmaceutical value chain, Gupta will play a pivotal role in steering global regulatory strategies and ensuring quality compliance for emerging, regulated, and semi-regulated markets.
Having served Intas Pharmaceuticals for the past 14 years across various roles, Gupta has a deep-rooted understanding of dossier compilation, life cycle management, GMP audits, and post-approval regulatory changes. His recent promotion to Assistant General Manager in April 2025 is a reflection of his exceptional contributions, especially in handling regulatory submissions for Brazil, Mexico, and multiple Latin American countries. He has been instrumental in preparing CTD-format dossiers, coordinating in-license documentation, and responding to complex regulatory queries.
Gupta’s earlier experiences at Jagsonpal Pharmaceuticals, Chemfar Organics, and Lark Laboratories further enriched his technical expertise in dossier development, packaging compliance, and international regulatory protocols. Throughout his journey, he has demonstrated a consistent ability to navigate diverse global regulatory landscapes while maintaining operational integrity and compliance excellence.
A postgraduate in Pharmaceutical Sciences from Rajiv Gandhi Prodyogiki Vishwavidyalaya and a B.Pharm graduate from Lachoo Memorial College, Gupta combines strong academic credentials with hands-on leadership. His tenure at Intas showcases a trajectory defined by continuous learning, impactful execution, and global regulatory acumen.
As Intas Pharmaceuticals continues to expand its footprint in emerging markets, Amit Gupta’s elevated role will be critical in shaping compliant and efficient product pathways worldwide. His leadership is expected to bolster the company’s commitment to quality, innovation, and regulatory excellence.
